1 July 2012 in Journal of the Academy of Nutrition and Dietetics
1 October 2020 in Journal of Clinical Investigation
The congenital sideroblastic anemias (CSAs) can be caused by primary defects in mitochondrial iron-sulfur (Fe-S) cluster biogenesis. HSCB (heat shock cognate B), which encodes a mitochondrial cochaperone, also known as HSC20 (heat shock cognate protein 20), is the partner of mitochondrial heat shock protein A9 (HSPA9). Together with glutaredoxin 5 (GLRX5), HSCB and HSPA9 facilitate the transfer of nascent 2-iron, 2-sulfur clusters to recipient mitochondrial proteins. Mutations in both HSPA9 and GLRX5 have previously been associated with CSA. Therefore, we hypothesized that mutations in HSCB could also cause CSA. We screened patients with genetically undefined CSA and identified a frameshift mutation and a rare promoter variant in HSCB in a female patient with non-syndromic CSA. We found that HSCB expression was decreased in patient-derived fibroblasts and K562 erythroleukemia cells engineered to have the patient-specific promoter variant. Furthermore, gene knockdown and deletion experiments performed in K562 cells, zebrafish, and mice demonstrate that loss of HSCB results in impaired Fe-S cluster biogenesis, a defect in RBC hemoglobinization, and the development of siderocytes and more broadly perturbs hematopoiesis in vivo. These results further affirm the involvement of Fe-S cluster biogenesis in erythropoiesis and hematopoiesis and define HSCB as a CSA gene.
20 November 2009 in Blood
Abstract 4056 Poster Board III-991
19 August 2021 in Pediatric Blood & Cancer
2 August 2023 in Annals of the New York Academy of Sciences
28 January 2026 in Public Health Reports®
Objective: An accurate estimate of the prevalence, demographic characteristics, and geographic distribution of thalassemia in the United States is needed to plan for the health care needs of people with this disease. We developed and evaluated the predictive value of administrative case definitions for correctly identifying people living with thalassemia. Methods: We conducted a retrospective study of the diagnostic accuracy of 3 claims-based case definitions to identify people with thalassemia in Medicaid administrative data from 2012 through 2019. Case definition 1 was ≥5 encounters with a code for thalassemia; case definition 2 was ≥1 encounter with a code for thalassemia and ≥6 encounters with a transfusion code; and case definition 3 was ≥2 encounters with a code for thalassemia and a transfusion code occurring on the same encounters. We validated our findings by using confirmatory laboratory assessment and expert review by clinicians at thalassemia treatment centers in Georgia (Children’s Healthcare of Atlanta) and California (University of California San Francisco) as the gold standard. Results: Of the 327 people identified, thalassemia was confirmed in 173 (52.9%), excluded in 68 (20.7%), and found indeterminate in 86 (26.2%) people. Case definition 1 had the lowest positive predictive value (PPV) (range, 55%-77%). For case definition 2, the PPV range was 80% to 86%. For case definition 3, the PPV range was the highest (82%-96%) but also captured more indeterminate cases. Conclusions: Accurately identifying patients with thalassemia using a case definition based on administrative claims data is feasible. Extending our method to other health care databases beyond Medicaid may allow for an estimate of the national prevalence of transfusion-dependent thalassemia. However, cases of nontransfusion-dependent thalassemia were difficult to define with sufficient precision.